NATCO Pharma Q3 results: Pharmaceutical company NATCO Pharma posted its results for the third quarter of fiscal 2024-25 (Q3 2025) on Wednesday reporting a 37.75% year-on-year (YoY) decline causing a drop of 19% in its shares on Thursday.
The company, post-market hours on Wednesday reported that its net profit dropped to ₹132.4 crore in the Q3 2025 compared to ₹212.7 crore in the previous quarter of last year.
NATCO Pharma Q3 results: The company’s consolidated revenue from operations declined by 37.4% to ₹474.8 crore in the third quarter from ₹758.6 crore last year.
NATCO Pharma Share price
Key reasons behind weak NATCO Pharma Q3 results
NATCO Pharma Q3 results: There could be several reasons behind the decline but the key reasons include the decline in export formulation business which is the biggest revenue contributor for the company. The export formulation revenue declined to ₹285.8 crore from ₹605.6 crore in the third quarter last year. The domestic formulation revenue was almost stable at ₹961 crore as against ₹994 crore on a YoY basis.
Coforge Q3 Results 2025: Revenue Up 40% at $397.1 Million
“Natco Pharma witnessed a significant decline in earnings during the quarter, primarily due to a drop in the export formulation business following the absence of Revlimid, its key revenue contributor. Domestic formulation sales also faced a downturn, further impacting overall performance. However, the company remains a strong player in the industry, benefiting from its vertically integrated structure and R&D-driven approach, focusing on niche therapeutic areas and complex products,” said Prathamesh Masdekar, Research Analyst, StoxBox.
What is Revlimid?
Revlimid or lenalidomide is a drug which is used to treat certain type of cancers. The actual drug is lenalidomide which is sold under the brand name of Revlimid and is taken orally.
